Kenvue Slides on HHS Plans to Link Autism to Tylenol Use in Pregnancy

Dow Jones
09/06
 

By Kelly Cloonan

 

Shares of Kenvue, a unit of which owns the Tylenol brand, declined amid plans from Health Secretary Robert F. Kennedy Jr. to announce that pregnant women's use of the over-the-counter medication is potentially linked to autism.

The stock fell 7.7%, to $18.98, midday Friday from trading near flat. Shares are down 11% this year.

The Department of Health and Human Services is expected to share a report this month citing Tylenol taken during pregnancy among potential causes of autism, The Wall Street Journal reported Friday, citing people familiar with the matter.

Tylenol, whose active ingredient is acetaminophen, is a widely used pain reliever, including by pregnant women. The brand is owned by McNeil Consumer Healthcare, a division of Kenvue.

Some previous studies have indicated Tylenol's risks to fetal development when used by pregnant women, but others have found no association.

"Nothing is more important to us than the health and safety of the people who use our products," a Kenvue spokeswoman said. "We have continuously evaluated the science and continue to believe there is no causal link between acetaminophen use during pregnancy and autism."

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

September 05, 2025 13:52 ET (17:52 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10